A superior tool to biopsies for the detection, localization and characterization of prostate cancer.

Many clinicians have encountered patients with negative sets of biopsies, only to have disease diagnosed at some point in the future. During a typical biopsy, only about 1% of the prostate is sampled. Biopsies miss approximately 20% of malignancies and often underestimate the extent of disease.


“MRI has been shown to identify cancer in more than half of men where the initial biopsies are negative.”

– UCLA’s David Geffen School of Medicine June 2011


“A group of investigators from Memorial Sloan-Kettering Cancer Center in New York report that adding endorectal MRI to the initial clinical evaluation of men with clinically low prostate cancer risk helps assess eligibility for active surveillance.”

– The Journal of Urology, September 24, 2012



  • The standard approach for prostate cancer detection is PSA screening followed by transrectal ultrasonography
  • (TRUS)-guided biopsy. This approach has low sensitivity and provides limited information about the true extent and aggressiveness of the cancer.1
  • The primary indication for MRI of the prostate is the evaluation of prostate cancer after positive diagnosis, but the test is now also recommended for patients with elevated prostatespecific antigen (PSA) levels or another prostate cancer variable, but who also have repeated negative biopsies.
  • The Siemens MAGNETOM Avanto 1.5T MRI at Santa Fe Imaging, used in conjunction with Sentinelle Dual Channel Endorectal Coil, provides excellent soft tissue image quality, which allows for a more accurate view of the entire prostate gland. The small coil profile allows for comfortable patient exams and minimal deformation of the prostate.
  • Total Imaging Matrix (TIM) coil technology delivers superior resolution and can determine cancer stage, conclude whether the cancer is contained and help determine the appropriate treatment for the patient.
  • Because lesion morphology can be difficult to assess, computer-aided detection helps the radiologist determine which areas of the prostate demonstrate rapid wash-in and wash-out of the contrast agent, an important tool to differentiate benign and malignant lesions.


Prostate MRI should be considered in men with:

  • Negative biopsies
  • PSA levels at more than 10 ng/mL and/ or increasing PSA levels
  • Small-volume, higher Gleason grade disease


For more information, or to consult with us about a specific patient, please call
(505) 983-9350.